ArticleScientific reports2025
LAMA3 overexpression enhances proliferation, migration and invasion in esophageal squamous cell carcinoma based on bioinformatics and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation.Histochemistry and cell biology · 2026Pooled it
- Stromal Laminin Subunit Alpha 3 is a Novel Prognostic Marker for Breast Cancer.Clinical Medicine Insights. Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignancy and remains a major public health burden worldwide, particularly in China, where both incidence and mortality rates are among the highest globally. Recent studies suggest that laminin subunit alpha 3 (LAMA3), a component of the basement membrane, may promote tumor progression; however, its specific role in ESCC remains unclear. In this study, we analyzed public RNA-sequencing data from TCGA and TIMER to evaluate LAMA3 expression and its clinical relevance in ESCC. We also validated LAMA3 protein and mRNA expression in clinical samples and cell lines using immunohistochemistry and RT-qPCR. Using siRNA, we established LAMA3-knockdown ESCC cell models and assessed cell proliferation, colony formation, migration, and invasion in vitro. LAMA3 expression was 2.4-fold higher in ESCC tumor tissues than in adjacent normal tissues (p < 0.001). High LAMA3 levels were associated with worse overall survival and disease-free survival (p < 0.05). Knockdown of LAMA3 suppressed cell proliferation by 57% (p < 0.001), migration by 49% (p < 0.001), and invasion by 47% (p < 0.001).Pathway enrichment analysis indicated involvement of LAMA3 and its co-expressed genes in cell adhesion, extracellular matrix organization, and the PI3K-AKT pathway. In summary, our results demonstrate that LAMA3 is a major promoter of ESCC progression and a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.